Medtronic plc (MDT) EPS Estimated At $1.38

May 23, 2018 - By Michael Collier

Medtronic plc (NYSE:MDT) LogoInvestors sentiment decreased to 1.02 in 2017 Q4. Its down 0.10, from 1.12 in 2017Q3. It dropped, as 65 investors sold Medtronic plc shares while 427 reduced holdings. 111 funds opened positions while 393 raised stakes. 1.04 billion shares or 2.98% less from 1.07 billion shares in 2017Q3 were reported.
Janney Montgomery Scott Limited Liability Co invested in 217,929 shares or 0.18% of the stock. 6,450 were reported by Opus Capital Grp Inc Limited Liability. Barrett Asset Management Ltd Liability Corp holds 1,826 shares or 0.01% of its portfolio. First Quadrant L P Ca accumulated 0.01% or 6,299 shares. Sii Investments Wi accumulated 3,349 shares or 0.03% of the stock. Confluence Invest Mngmt Limited Liability, a Missouri-based fund reported 200,406 shares. Ci holds 0.72% in Medtronic plc (NYSE:MDT) or 929,851 shares. First Tru stated it has 39,135 shares. Hanson Doremus Inv Mngmt has invested 0.41% in Medtronic plc (NYSE:MDT). Plante Moran Fincl Lc invested in 0.05% or 1,191 shares. Strategic Financial Svcs holds 0.73% or 57,515 shares in its portfolio. Invesco stated it has 0.21% in Medtronic plc (NYSE:MDT). First Merchants has invested 0.65% in Medtronic plc (NYSE:MDT). Cap Int Ca invested in 21,300 shares or 0.26% of the stock. Massachusetts-based Bollard Grp Ltd Liability Com has invested 0.01% in Medtronic plc (NYSE:MDT).

Analysts expect Medtronic plc (NYSE:MDT) to report $1.38 EPS on May, 24 before the open.They anticipate $0.05 EPS change or 3.76 % from last quarter’s $1.33 EPS. MDT’s profit would be $1.87B giving it 15.39 P/E if the $1.38 EPS is correct. After having $1.17 EPS previously, Medtronic plc’s analysts see 17.95 % EPS growth. The stock decreased 0.41% or $0.35 during the last trading session, reaching $84.97. About 4.59 million shares traded. Medtronic plc (NYSE:MDT) has declined 3.54% since May 23, 2017 and is downtrending. It has underperformed by 15.09% the S&P500.

Medtronic plc (NYSE:MDT) Ratings Coverage

Among 8 analysts covering Medtronic (NYSE:MDT), 7 have Buy rating, 0 Sell and 1 Hold. Therefore 88% are positive. Medtronic has $95.0 highest and $9000 lowest target. $92.79’s average target is 9.20% above currents $84.97 stock price. Medtronic had 9 analyst reports since December 12, 2017 according to SRatingsIntel. Citigroup maintained the stock with “Buy” rating in Thursday, February 22 report. Needham maintained the shares of MDT in report on Wednesday, February 21 with “Buy” rating. The firm earned “Buy” rating on Tuesday, January 2 by Bank of America. The rating was maintained by Morgan Stanley with “Equal-Weight” on Thursday, March 29. Piper Jaffray initiated the stock with “Buy” rating in Friday, April 27 report. As per Monday, February 5, the company rating was maintained by Morgan Stanley. BMO Capital Markets maintained the stock with “Buy” rating in Tuesday, December 12 report. The firm earned “Buy” rating on Tuesday, December 12 by Argus Research.

Medtronic plc manufactures and sells device medical therapies to hospitals, physicians, clinicians, and patients worldwide. The company has market cap of $115.17 billion. The company's Cardiac and Vascular Group segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; diagnostics and monitoring devices; mechanical circulatory support, TYRX, and AF products; and remote monitoring and patient-centered software. It has a 41.57 P/E ratio. It also provides transcatheter heart valves, percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, peripheral vascular products, and products to treat superficial and deep venous diseases.

More important recent Medtronic plc (NYSE:MDT) news were published by: which released: “Medtronic Should Focus On Aggressive Deleveraging” on May 15, 2018, also published article titled: “Polaris, Securian join ranks of Fortune 500 companies; UnitedHealth moves into Top 5 (slideshow)”, published: “Medtronic Announces 2018 Institutional Investor and Analyst Meeting and Webcast” on May 18, 2018. More interesting news about Medtronic plc (NYSE:MDT) was released by: and their article: “New Medtronic Data Show Significant Blood Pressure Lowering Effect of Renal Denervation in Patients Taking Anti …” with publication date: May 23, 2018.

Medtronic plc (NYSE:MDT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.